{
    "eid": "2-s2.0-85167436418",
    "title": "Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance",
    "cover-date": "2023-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Immunology and Microbiology (all)",
            "@code": "2400",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Veterinary (all)",
            "@code": "3400",
            "@abbrev": "VETE"
        },
        {
            "@_fa": "true",
            "$": "Public Health, Environmental and Occupational Health",
            "@code": "2739",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Anti-SARS-CoV-2 IgG",
        "BNT162b2 vaccine",
        "Child",
        "Infant",
        "Neutralizing antibody titer",
        "SARS-CoV-2 vaccine"
    ],
    "authors": [
        "Rapisa Nantanee",
        "Peera Jaru-Ampornpan",
        "Napaporn Chantasrisawad",
        "Orawan Himananto",
        "Supawan Papakhee",
        "Jiratchaya Sophonphan",
        "Monta Tawan",
        "Thidarat Jupimai",
        "Suvaporn Anugulruengkitt",
        "Thanyawee Puthanakit"
    ],
    "citedby-count": 0,
    "ref-count": 30,
    "ref-list": [
        "Pediatric Infection-Induced SARS-CoV-2 Seroprevalence Increases and Seroprevalence by Type of Clinical Care September 2021 to February 2022",
        "Evaluation of BNT162b2 Covid-19 vaccine in children younger than 5 years of age",
        "Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022",
        "Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3\u20135 Years - Increasing Community Access to Testing Program, United States, July 2022-February 2023",
        "Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis",
        "Effects of Vaccination and Previous Infection on Omicron Infections in Children",
        "Coronavirus Disease 2019 Vaccine Boosting in Previously Infected or Vaccinated Individuals",
        "Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression",
        "Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection",
        "A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction",
        "A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines",
        "Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac",
        "A serological assay to detect SARS-CoV-2 seroconversion in humans",
        "COVID-19 vaccine hesitancy and influential factors among Thai parents and guardians to vaccinate their children",
        "Misinformation about vaccine safety and uptake of COVID-19 vaccines among adults and 5\u201311-year-olds in the United States",
        "Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses",
        "Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine",
        "Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022",
        "Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial",
        "Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60011947",
            "affilname": "Thailand National Center for Genetic Engineering and Biotechnology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011947",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Center of Excellence for Pediatric Infectious Diseases and Vaccines",
        "Chula Clinical Research Center, Faculty of Medicine, Chulalongkorn University",
        "Department of Diseases Control",
        "HIV Netherlands Australia Thailand Research Collaboration",
        "Monoclonal Antibody Production and Application Research Team",
        "National Vaccine Institute, Thailand",
        "National Vaccine Institutes",
        "Department of Pediatrics",
        "Chulalongkorn University",
        "Ministry of Public Health, Thailand",
        "BIOTEC"
    ]
}